The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Ondine Biomedical Pretax Margin % Related Terms
Ondine Biomedical Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Ondine Biomedical's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LSE:OBI vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Ondine Biomedical's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ondine Biomedical Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Ondine Biomedical's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ondine Biomedical (LSE:OBI) has a Pretax Margin % of -1,038.80% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ondine Biomedical and its competitors. According to the industry distribution chart, Ondine Biomedical ranks #751 out of 941 companies in the Biotechnology industry, placing it in the top 79.8%.
Is Ondine Biomedical's Pretax Margin % too high?
Ondine Biomedical's current Pretax Margin % is -1,038.80%. Based on the distribution chart, Ondine Biomedical ranks #751 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ondine Biomedical has a GF Score™ of 28/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ondine Biomedical ranks #751 out of 941 companies for Pretax Margin %. This places Ondine Biomedical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Ondine Biomedical and its competitors. Ondine Biomedical's current Pretax Margin % is -1,038.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (LSE:OBI) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.10, compared to a current price of £0.15 — trading 45% above its estimated fair value. The current Pretax Margin % is -1,038.80%. Ondine Biomedical's overall GF Score™ is 28/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Ondine Biomedical (LSE:OBI), the current Pretax Margin % is -1,038.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ondine Biomedical (LSE:OBI) Overvalued in 2026?
Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued.
The current stock price of £0.15 is trading 45% above its estimated GF Value™ of £0.10.
GuruFocus considers Ondine Biomedical to be Significantly Overvalued.
Key valuation signals for LSE:OBI:
Pretax Margin %: -1,038.80%
GF Value™: £0.10 vs. price of £0.15 (45% above fair value)
No single metric tells the full story. See the LSE:OBI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
28GF Score
Get the complete analysis for LSE:OBI
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:OBI has been successfully added to your 
